Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Genetic Variants in ASCT2 Gene are Associated with the Prognosis of Transarterial Chemoembolisation-Treated Early-Stage Hepatocelluar Carcinoma

  • Ge, Nai-Jian (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University) ;
  • Shi, Zhi-Yong (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University) ;
  • Yu, Xiao-He (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University) ;
  • Huang, Xiao-Jun (State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University) ;
  • Wu, You-Sheng (State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University) ;
  • Chen, Yuan-Yuan (Department of Ophthalmology, First People of Yulin) ;
  • Zhang, Jin (State Key Laboratory of Cancer Biology and Experimental Teaching Center of Basic Medicine, Fourth Military Medical University) ;
  • Yang, Ye-Fa (Department of Radioactive Intervention, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University)
  • Published : 2015.05.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies worldwide. Transarterial chemoembolisation (TACE) is the standardized therapy for intermediate stage HCC. However, the prognosis for HCC patients treated by TACE greatly varies. Thus, there is a critical need for finding biomarkers to predict the prognosis of HCC patients. The amino acid transporter-2 (ASCT2) is involved in tumorigenesis and progression of many malignancies. This study aimed to evaluate the predictive role of two single nuclear polymorphisms (SNPs, rs3826793 and rs2070246) in the ASCT2 gene in HCC patients treated by TACE. Materials and Methods: Two functional SNPs (rs3826793 and rs2070246) in the ASCT2 gene were selected and genotyped using the Sequenom iPLEX genotyping system in a cohort of 448 unresectable Chinese HCC patients treated by TACE. Univariate and multivariate Cox proportional hazards models and Kaplan-Meier curves were used for the prognosis analyses. Results: There was no significant association between two SNPs (rs3826793 and rs2070246) in the ASCT2 gene and overall survival of TACE treated HCC patients. However, we demonstrated that patients with early stage HCC carrying T genotype in rs2070246 showed better OS than those carrying CC genotype (P=0.023). Conclusions: We demonstrated that patients with early stage HCC carrying T genotype in rs2070246 showed better OS than those carrying CC genotype.

Keywords

References

  1. Bruix J, Sherman M, American Association for the Study of Liver D (2011). Management of hepatocellular carcinoma: an update. Hepatology, 53, 1020-2. https://doi.org/10.1002/hep.24199
  2. Chamary JV, Parmley JL, Hurst LD (2006). Hearing silence: non-neutral evolution at synonymous sites in mammals. Nat Rev Genet, 7, 98-108. https://doi.org/10.1038/nrg1770
  3. Fuchs A, Colonna M (2006). The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance. Semin Cancer Biol, 16, 359-66. https://doi.org/10.1016/j.semcancer.2006.07.002
  4. Fuchs BC, Finger RE, Onan MC, et al (2007). ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol, 293, 55-63. https://doi.org/10.1152/ajpcell.00330.2006
  5. Hensley CT, Wasti AT, DeBerardinis RJ (2013). Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest, 123, 3678-84. https://doi.org/10.1172/JCI69600
  6. Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  7. Kohles N, Nagel D, Jungst D, et al (2012). Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol, 33, 33-40. https://doi.org/10.1007/s13277-011-0237-7
  8. Li R, Younes M, Frolov A, et al (2003). Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res, 23, 3413-8.
  9. Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatol, 37, 429-42. https://doi.org/10.1053/jhep.2003.50047
  10. Llovet JM, Real MI, Montana X, et al (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet, 359, 1734-9. https://doi.org/10.1016/S0140-6736(02)08649-X
  11. Mazurek S, Eigenbrodt E (2003). The tumor metabolome. Anticancer Res, 23, 1149-54.
  12. Mullen AR, Hu Z, Shi X, et al (2014). Oxidation of alphaketoglutarate is required for reductive carboxylation in cancer cells with mitochondrial defects. Cell Rep, 7, 1679-90. https://doi.org/10.1016/j.celrep.2014.04.037
  13. Namikawa M, Kakizaki S, Kaira K, et al (2014). Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res.
  14. Reynolds MR, Lane AN, Robertson B, et al (2014). Control of glutamine metabolism by the tumor suppressor Rb. Oncogene, 33, 556-66. https://doi.org/10.1038/onc.2012.635
  15. Shastry BS (2009). SNPs: impact on gene function and phenotype. Methods Mol Biol, 578, 3-22. https://doi.org/10.1007/978-1-60327-411-1_1

Cited by

  1. RNA Splicing and Correlates with Human Longevity pp.1557-8577, 2018, https://doi.org/10.1089/rej.2017.1948